Investment Banking
An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.
Complete the form below to download your copy of the report
Stay up-to-date with the latest William Blair news and insights
In this Economics Weekly, Richard de Chazal looks at the U.S. consumer, with the view that they are still resilient, even as they face some headwinds. Simply put, this is not a consumer-driven recovery—it’s a capex one.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
